ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
2,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
3,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
3,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
4,1,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
5,1,Purpura,Purpura and related conditions,Skin vascular abnormalities,Skin,N
6,1,Granulocytopenia,Neutropenias,White blood cell disorders,Blood,N
7,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
8,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
9,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
9,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
10,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
11,1,Candida infection,Candida infections,Fungal infectious disorders,Infec,N
11,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
12,1,Eczema,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
13,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
14,1,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
15,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
16,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
16,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
16,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
17,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
18,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
18,2,Vaginal haemorrhage,Vulvovaginal disorders NEC,Vulvovaginal disorders (excl infections and inflammations),Repro,N
19,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
19,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
19,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
19,4,Product substitution issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
19,5,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
20,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
20,2,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
21,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
21,2,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
22,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
22,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
23,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
23,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
24,1,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
25,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
25,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
25,3,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
26,1,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
26,2,Seborrhoea,Sebaceous gland disorders,Skin appendage conditions,Skin,N
27,1,Mouth swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
28,1,Application site burn,Application site reactions,Administration site reactions,Genrl,N
28,2,Application site erythema,Application site reactions,Administration site reactions,Genrl,N
28,3,Application site paraesthesia,Application site reactions,Administration site reactions,Genrl,N
28,4,Application site pruritus,Application site reactions,Administration site reactions,Genrl,N
28,5,Application site warmth,Application site reactions,Administration site reactions,Genrl,N
28,6,Product physical consistency issue,Product physical issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
29,1,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
29,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
29,3,Skin exfoliation,Exfoliative conditions,Epidermal and dermal conditions,Skin,N
30,1,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
30,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
31,1,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
31,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
32,1,Dermatitis allergic,Dermatitis and eczema,Epidermal and dermal conditions,Skin,N
32,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
